Pyrazinamide: Clinical Trials

44 trials of Pyrazinamide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 7 recruiting, 6 not yet recruiting, 4 terminated. 44 Phase 2, 6 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 244Completed 21, Recruiting 7, Not yet recruiting 6, Terminated 4, Active not recruiting 3, Suspended 2, Unknown 1
Phase 36Completed 5, Active not recruiting 1
Phase 11Completed 1

Follow Pyrazinamide: new trials by email Literature Review of Pyrazinamide trials Research Report on Pyrazinamide

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Re-evaluating the Duration in Children of TB Treatment
Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis
Phase 2Not yet recruitingUniversity of Wisconsin, Madison2302027-02-012026-11-02
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Isoniazid, Rifampin, Pyrazinamide - Tuberculosis
Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)9002026-10-302026-08-19
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary
Phase 2Not yet recruitingTASK Applied Science1352026-09-252026-09-25
AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT
Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis
Phase 2Not yet recruitingMinistry of Health, Saudi Arabia2002026-09-012026-03-12
ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)
Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg - Pulmonary Tuberculosis (TB)
Phase 2RecruitingObafemi Awolowo University Teaching Hospital802026-01-032026-01-23
Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
RESP30TB, HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) - Pulmonary Tuberculoses
Phase 2RecruitingThirty Respiratory Limited242025-10-132026-01-12
Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis
Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis
Phase 2Not yet recruitingShanghai Pulmonary Hospital, Shanghai, China452025-08-202025-08-19
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
Rifampin, Isoniazid, Rifapentine (RPT) - Mild Spinal Tuberculosis
Phase 2Not yet recruitingShandong University3002025-04-052025-04-08
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis
Phase 2SuspendedNational Institute of Allergy and Infectious Diseases (NIAID)3412025-03-112026-11-02
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis
Phase 2RecruitingTASK Applied Science602025-03-032025-03-07
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis
Phase 2RecruitingUniversity College, London25002024-01-092026-10-15
ATORvastatin in Pulmonary TUBerculosis
Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis
Phase 2RecruitingObafemi Awolowo University Teaching Hospital4402024-01-032025-09-25
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD) - Tuberculous Meningitis
Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)3302023-12-072026-06-02
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis
Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV
Phase 2Active not recruitingBrigham and Women's Hospital942023-11-242026-08-05
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection
Phase 2 / Phase 3Active not recruitingCenters for Disease Control and Prevention2882023-11-212026-09-21
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis
Phase 2Active not recruitingGlobal Alliance for TB Drug Development3092023-10-312026-06-24
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis
Phase 2TerminatedGates Medical Research Institute932023-07-262026-05-20
PanACEA - STEP2C -01
BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
Phase 2RecruitingMichael Hoelscher3902023-04-142025-10-07
Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
rifampicin, pyrazinamide, HRZE - Tuberculosis, Pulmonary
Phase 2SuspendedUniversity Hospital, Linkoeping402022-11-302026-08-17
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
Isoniazid, Rifampicin, Ethambutol - Tuberculosis, Pulmonary Tuberculosis
Phase 2CompletedUniversity of Massachusetts, Worcester1122022-03-042026-08-06

Showing 20 of 44. Sign in to see all of them.

Conditions studied

Tuberculosis, Pulmonary (30)  ·  Tuberculosis (29)  ·  Tuberculosis, Multidrug-Resistant (6)  ·  HIV Infections (4)  ·  Extensively Drug-Resistant Tuberculosis (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Central Nervous System Diseases (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Latent Tuberculosis (1)  ·  Tuberculosis, Meningeal (1)

Sponsors

Global Alliance for TB Drug Development (7)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (6)  ·  Centers for Disease Control and Prevention (3)  ·  Michael Hoelscher (3)  ·  Obafemi Awolowo University Teaching Hospital (3)  ·  TASK Applied Science (3)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2)  ·  Johns Hopkins University (2)  ·  University College, London (2)  ·  Brigham and Women's Hospital (1)  ·  French National Agency for Research on AIDS and Viral Hepatitis (1)  ·  Gates Medical Research Institute (1)  ·  Ministry of Health, Saudi Arabia (1)  ·  National University Hospital, Singapore (1)  ·  Seoul National University Hospital (1)

Countries

South Africa (30)  ·  Uganda (12)  ·  Tanzania (9)  ·  Philippines (8)  ·  Brazil (7)  ·  Haiti (6)  ·  Vietnam (6)  ·  India (5)  ·  Malawi (5)  ·  Peru (5)  ·  Kenya (4)  ·  Thailand (4)  ·  Zimbabwe (4)  ·  Canada (3)  ·  Georgia (3)

Top investigators

Bolanle A Omotoso, MD (3)  ·  Nicholas Paton (2)  ·  Olanisun O Adewole, MD (2)  ·  Richard E Chaisson, MD (2)  ·  Susan Dorman, MD (2)  ·  Andreas Diacon (1)  ·  Andreas Diacon, MD (1)  ·  Andreas Diacon, MD, PhD (1)  ·  Andreas Diacon, Prof (1)  ·  Anthony Garcia-Prats, MD, MSc, PhD (1)  ·  Antonio Lombardi, MD (1)  ·  Clifton E Barry, Ph.D. (1)  ·  Constance A Benson, MD (1)  ·  Daniel W Fitzgerald, MD (1)

Results publications

PMID 33542052, PMID 36808186, PMID 38768617, PMID 16675781, PMID 19406981, PMID 21494548, PMID 22828481, PMID 23433590, PMID 24663014, PMID 25622149, PMID 25795076, PMID 27159505, PMID 27550361, PMID 28100438, PMID 28739794, PMID 29528048, PMID 30102705, PMID 30651149, PMID 31732485, PMID 31932382, PMID 33229425, PMID 33834177, PMID 35175905, PMID 35273049, PMID 35315690, PMID 36455068, PMID 36522208, PMID 36966799, PMID 39622823, PMID 39651910, PMID 39793592, PMID 40195983, PMID 40414233, PMID 40817073, PMID 40915311, PMID 40915316, PMID 41487489, PMID 41510291, PMID 41616265, PMID 42560062, PMID 42568101

NIH funding

U01AI068636 (2), 2019 (1), U01AI134585 (1), U01AI170426 (1), U01AI192041 (1)